Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Pipeline Review, H2 2016

  • ID: 3989548
  • Report
  • 187 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Amgen Inc.
  • AstraZeneca Plc
  • BioArctic AB
  • Eddingpharm
  • F. Hoffmann-La Roche Ltd.
  • Metacrine Inc
  • MORE
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Pipeline Review, H2 2016

Summary

‘Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Pipeline Review, H2 2016’, provides in depth analysis on Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
Certain sections in the report may be removed or altered based on the availability and relevance of data.
Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1)
- The report reviews Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Amgen Inc.
  • AstraZeneca Plc
  • BioArctic AB
  • Eddingpharm
  • F. Hoffmann-La Roche Ltd.
  • Metacrine Inc
  • MORE
List of Tabless

List of Figures

-Introduction

Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) Overview

-Therapeutics Development

-Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Products under Development by Stage of Development

-Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Products under Development by Therapy Area

-Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Products under Development by Indication

-Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Pipeline Products Glance

-Late Stage Products

-Early Stage Products

-Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Products under Development by Companies

-Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Products under Development by Universities/Institutes

-Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Therapeutics Assessment

-Assessment by Monotherapy/Combination Products

-Assessment by Mechanism of Action

-Assessment by Route of Administration

-Assessment by Molecule Type

-Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Companies Involved in Therapeutics Development

-Advenchen Laboratories, LLC

-Amgen Inc.

-ArQule, Inc.

-Astellas Pharma Inc.

-AstraZeneca Plc

-Asubio Pharma Co., Ltd.

-AVEO Pharmaceuticals, Inc.

-Bayer AG

-BioArctic AB

-Boehringer Ingelheim GmbH

-Bristol-Myers Squibb Company

-CardioVascular BioTherapeutics, Inc.

-Celon Pharma Sp. z o.o.

-Debiopharm International SA

-Eddingpharm

-Eisai Co., Ltd.

-Eli Lilly and Company

-F. Hoffmann-La Roche Ltd.

-Hutchison MediPharma Limited

-Incyte Corporation

-Johnson & Johnson

-Les Laboratoires Servier SAS

-Metacrine Inc

-Novartis AG

-OncoMax

-Principia Biopharma Inc.

-Teva Pharmaceutical Industries Ltd.

-Vichem Chemie Research Ltd.

-Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Drug Profiles

-Aea-25 - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-Aea-4 - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-ARQ-087 - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-ASP-5878 - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-AZD-4547 - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-BAY-1163877 - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-BMS-986036 - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-brivanib alaninate - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-CEP-11981 - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-CPL-043 - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-CVBT-141B - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-CVBT-141C - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-CVBT-141D - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-CVBT-141H - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-Debio-1347 - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-Drugs to Agonize Fibroblast Growth Factor Receptor 1 for Type 2 Diabetes - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-E-7090 - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-EDP-317 - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-erdafitinib - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-FGF-1 Program - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-HMPL-012 - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-HMPL-453 - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-INCB-54828 - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-infigratinib - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-lenvatinib mesylate - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-lucitanib - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-LY-2874455 - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-Monoclonal Antibody to Antagonize FGFR1 for Cancer - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-nintedanib - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-OMRCA-01 - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-pazopanib hydrochloride - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-pazopanib hydrochloride + pembrolizumab - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-PRN-1371 - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-Recombinant Protein to Agonize FGFR for Type 2 Diabetes - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-Recombinant Proteins to Agonize FGFR for Metabolic Disorders - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-regorafenib - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-RG-7992 - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-S-49076 - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-SC-0806 - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-Small Molecules to Antagonize Pan FGFR for Oncology - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-SUN-11602 - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Dormant Projects

-Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Discontinued Products

-Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Featured News & Press Releases

-Nov 07, 2016: Bayer Submits Supplemental New Drug Application for Stivarga (regorafenib) for Advanced Liver Cancer

-Nov 07, 2016: Regorafenib from Bayer Submitted to Health Authorities Seeking Approval in Second-Line Treatment of Liver Cancer

-Oct 26, 2016: Eisais LENVIMA (lenvatinib) Nominated for Galien Foundations Best Pharmaceutical Product

-Oct 24, 2016: Efficacy of Ofev (nintedanib) Reinforced in Range of Patients with IPF in New Analyses Presented at CHEST

-Oct 12, 2016: Preliminary Phase Ib Clinical Study Results for Lenvatinib in Combination with Pembrolizumab in Selected Solid Tumors Presented at ESMO 2016

-Oct 09, 2016: ESMO 2016: Lenvatinib Shows Promising Activity in Patients with RET-Positive Adenocarcinoma of the Lung

-Oct 09, 2016: People with an Advanced Form of Thyroid Cancer Now Able to Benefit From Lenvima (lenvatinib) in Scotland

-Oct 09, 2016: Phase III nintedanib trial results in patients with metastatic colorectal cancer announced at ESMO

-Oct 08, 2016: Phase I study of novel anti-cancer drug uses tumor mRNA expression to identify responders

-Sep 30, 2016: Eisai To Initiate Phase III Clinical Study Of Anticancer Agent Lenvatinib As Potential First-Line Therapy For Advanced Renal Cell Carcinoma

-Sep 29, 2016: Eisai To Present Latest Data On Lenvatinib At ESMO Congress 2016

-Sep 28, 2016: Bayer to Showcase Regorafenib at ESMO 2016 Congress

-Sep 28, 2016: Bayer presents New Data on BAY 1163877 at ESMO 2016 Congress

-Sep 21, 2016: Eisai to Present Updates on Lenvatinib in Two Types of Thyroid Cancer at 86th Annual Meeting of the American Thyroid Association

-Sep 15, 2016: Eisai Receives License For New Indication For Anticancer Agent Kisplyx (Lenvatinib Mesylate) For Treatment Of Advanced Renal Cell Carcinoma

-Appendix

-Methodology

-Coverage

-Secondary Research

-Primary Research

-Expert Panel Validation

-Contact Us

-Disclaimer

List of Tabless

-Number of Products under Development for, H2 2016

-Number of Products under Development by Therapy Area, H2 2016

-Number of Products under Development by Indication, H2 2016

-Comparative Analysis by Late Stage Development, H2 2016

-Comparative Analysis by Early Stage Products, H2 2016

-Number of Products under Development by Companies, H2 2016

-Number of Products under Development by Companies, H2 2016 (Contd..1)

-Products under Development by Companies, H2 2016

-Products under Development by Companies, H2 2016 (Contd..1)

-Products under Development by Companies, H2 2016 (Contd..2)

-Products under Development by Companies, H2 2016 (Contd..3)

-Products under Development by Companies, H2 2016 (Contd..4)

-Products under Development by Companies, H2 2016 (Contd..5)

-Products under Development by Companies, H2 2016 (Contd..6)

-Products under Development by Companies, H2 2016 (Contd..7)

-Products under Development by Companies, H2 2016 (Contd..8)

-Number of Products under Investigation by Universities/Institutes, H2 2016

-Products under Investigation by Universities/Institutes, H2 2016

-Assessment by Monotherapy/Combination Products, H2 2016

-Number of Products by Stage and Mechanism of Action, H2 2016

-Number of Products by Stage and Route of Administration, H2 2016

-Number of Products by Stage and Molecule Type, H2 2016

-Pipeline by Advenchen Laboratories, LLC, H2 2016

-Pipeline by Amgen Inc., H2 2016

-Pipeline by ArQule, Inc., H2 2016

-Pipeline by Astellas Pharma Inc., H2 2016

-Pipeline by AstraZeneca Plc, H2 2016

-Pipeline by Asubio Pharma Co., Ltd., H2 2016

-Pipeline by AVEO Pharmaceuticals, Inc., H2 2016

-Pipeline by Bayer AG, H2 2016

-Pipeline by BioArctic AB, H2 2016

-Pipeline by Boehringer Ingelheim GmbH, H2 2016

-Pipeline by Bristol-Myers Squibb Company, H2 2016

-Pipeline by CardioVascular BioTherapeutics, Inc., H2 2016

-Pipeline by Celon Pharma Sp. z o.o., H2 2016

-Pipeline by Debiopharm International SA, H2 2016

-Pipeline by Eddingpharm, H2 2016

-Pipeline by Eisai Co., Ltd., H2 2016

-Pipeline by Eli Lilly and Company, H2 2016

-Pipeline by F. Hoffmann-La Roche Ltd., H2 2016

-Pipeline by Hutchison MediPharma Limited, H2 2016

-Pipeline by Incyte Corporation, H2 2016

-Pipeline by Johnson & Johnson, H2 2016

-Pipeline by Les Laboratoires Servier SAS, H2 2016

-Pipeline by Metacrine Inc, H2 2016

-Pipeline by Novartis AG, H2 2016

-Pipeline by OncoMax, H2 2016

-Pipeline by Principia Biopharma Inc., H2 2016

-Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016

-Pipeline by Vichem Chemie Research Ltd., H2 2016

-Dormant Projects, H2 2016

-Dormant Projects (Contd..1), H2 2016

-Dormant Projects (Contd..2), H2 2016

-Dormant Projects (Contd..3), H2 2016

-Dormant Projects (Contd..4), H2 2016

-Discontinued Products, H2 2016

-Discontinued Products (Contd..1), H2 2016

-Discontinued Products (Contd..2), H2 2016

List of Figures

-Number of Products under Development for, H2 2016

-Number of Products under Development by Therapy Area, H2 2016

-Number of Products under Development by Top 10 Indication, H2 2016

-Comparative Analysis by Late Stage Development, H2 2016

-Comparative Analysis by Early Stage Products, H2 2016

-Assessment by Monotherapy/Combination Products, H2 2016

-Number of Products by Mechanism of Actions, H2 2016

-Number of Products by Stage and Mechanism of Actions, H2 2016

-Number of Products by Routes of Administration, H2 2016

-Number of Products by Stage and Routes of Administration, H2 2016

-Number of Products by Molecule Types, H2 2016

-Number of Products by Stage and Molecule Type, H2 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Advenchen Laboratories, LLC
  • Amgen Inc.
  • ArQule, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Asubio Pharma Co., Ltd.
  • AVEO Pharmaceuticals, Inc.
  • Bayer AG
  • BioArctic AB
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • CardioVascular BioTherapeutics, Inc.
  • Celon Pharma Sp. z o.o.
  • Debiopharm International SA
  • Eddingpharm
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Hutchison MediPharma Limited
  • Incyte Corporation
  • Johnson & Johnson
  • Les Laboratoires Servier SAS
  • Metacrine Inc
  • Novartis AG
  • OncoMax
  • Principia Biopharma Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Vichem Chemie Research Ltd.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll